Skip to main content
Erschienen in:

22.09.2021

Developing a Novel Interactive Colorectal Cancer Educational Session for First-Year Medical Students to Enhance Interest in Public Health

verfasst von: Roselande Marcellon, Katherine Donovan, Helen Zhou, Shane Fiust-Klink, William Calawerts, Mihir Patel, Olivia Watman, David Miller, Paul Sorum, Kallanna Manjunath, Rebecca Stetzer, Danielle Wales, Hyacinth Mason, Michael Waxman, Heather Dacus, Paul Feustel, Michael Tadros

Erschienen in: Journal of Cancer Education | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Medical students need more exposure to and a greater understanding of their role in public health throughout their training, which may influence more of them to pursue careers in public health or change how they practice medicine in the future. A novel colorectal cancer education session was created for first year medical students to attempt to increase public health interest, improve colorectal cancer knowledge and discuss barriers to colorectal cancer screening. We constructed a novel integrated interactive peer led colorectal cancer educational session of panelists with a wide range of experiences in colorectal cancer and colorectal cancer screening. The session involved a didactic component, case presentation, and group exercises followed by assembly discussion. We surveyed first-year medical students over two consecutive years to assess their interest in public health, knowledge of colorectal cancer, and perceptions of barriers to colorectal cancer screening before and after the educational session. We also evaluated student satisfaction with the session. We compared the pre- and post-survey results to assess for changes in interest, knowledge and perceptions. 74.63% of students in 2018 and 67.7% in 2019 evaluated the session as excellent or good, with knowledge regarding colorectal cancer screening markedly increased after the educational session. Students reported knowledge and access to healthcare among the biggest patient barriers to colorectal cancer screening. Interest in public health increased by 7.5% and 5.6% in 2018 and 2019, respectively. The implementation of this interactive educational peer led exercise can increase interest in public health, improve knowledge of colorectal cancer prevention and facilitate discussions of colorectal cancer screening barriers. We hope to encourage other programs to adopt this preliminary model.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Maeshiro R, Johnson I, Koo D, Parboosingh J, Carney JK, Gesundheit N et al (2010) Medical education for a healthier population: reflections on the Flexner Report from a public health perspective. Acad Med 85(2):211–219CrossRef Maeshiro R, Johnson I, Koo D, Parboosingh J, Carney JK, Gesundheit N et al (2010) Medical education for a healthier population: reflections on the Flexner Report from a public health perspective. Acad Med 85(2):211–219CrossRef
2.
Zurück zum Zitat Mahoney JF, Fox MD, Chheda SG (2011) Overcoming challenges to integrating public and population health into medical curricula. Am J Prev Med 41(4 Suppl 3):S170–S175CrossRef Mahoney JF, Fox MD, Chheda SG (2011) Overcoming challenges to integrating public and population health into medical curricula. Am J Prev Med 41(4 Suppl 3):S170–S175CrossRef
3.
Zurück zum Zitat Koo K, Lapp I (2014) Educating the next generation of physicians in public health: the MPH for medical students. Public Health Rep 129(5):460–464CrossRef Koo K, Lapp I (2014) Educating the next generation of physicians in public health: the MPH for medical students. Public Health Rep 129(5):460–464CrossRef
4.
Zurück zum Zitat Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. Bmj-Brit Med J. 2014;348. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. Bmj-Brit Med J. 2014;348.
5.
Zurück zum Zitat Brtnikova M, Crane LA, Allison MA, Hurley LP, Beaty BL, Kempe A. A method for achieving high response rates in national surveys of U.S. primary care physicians. PLoS One. 2018;13(8):e0202755. Brtnikova M, Crane LA, Allison MA, Hurley LP, Beaty BL, Kempe A. A method for achieving high response rates in national surveys of U.S. primary care physicians. PLoS One. 2018;13(8):e0202755.
Metadaten
Titel
Developing a Novel Interactive Colorectal Cancer Educational Session for First-Year Medical Students to Enhance Interest in Public Health
verfasst von
Roselande Marcellon
Katherine Donovan
Helen Zhou
Shane Fiust-Klink
William Calawerts
Mihir Patel
Olivia Watman
David Miller
Paul Sorum
Kallanna Manjunath
Rebecca Stetzer
Danielle Wales
Hyacinth Mason
Michael Waxman
Heather Dacus
Paul Feustel
Michael Tadros
Publikationsdatum
22.09.2021
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 1/2023
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-021-02087-y

Neu im Fachgebiet Onkologie

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Brustkrebstherapie: zu wenig Aufklärung über Nebenwirkungen?

Ergebnisse eines internationalen Surveys legen nahe, dass die Aufklärung über Nebenwirkungen einer Brustkrebstherapie häufig unzureichend ausfällt bzw. zu spät erfolgt.

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.